Technology Bundle ID
TAB-3539

RALDH1 Inhibitors for the Immunotherapy of Hepatocellular Carcinoma

Applications
Linked ID
E-041-2021-0
Lead Inventors
Ganesha Rai Bantukallu (NCATS)
Co-Inventors
Adam Yasgar (NCATS)
Alexey Zakharov (NCATS)
Anton Simeonov (NCATS)
Malay Haldar (University of Pennsylvania)
Natalia Martinez (NCATS)
Shyh Yang (NCATS)
ICs
This technology includes the utility of the novel small molecule inhibitors of ALDH1A1 (RALDH1) in combination with immunotherapy for the treatment of hepatocellular carcinoma (HCC). Recently it was shown that the ALDH1A1 catalyzed production of retinoic acid (RA) in tumor cells promotes their differentiation into immunosuppressive antigen-presenting cells. Therefore, blocking RA production by tumor cells and/or blocking RA signaling in monocytes using our ALDH1A1 inhibitors can alleviate immunosuppression and engender anti-tumor immune responses.
Commercial Applications
Treatment of hepatocellular carcinoma and other solid tumors where the RA-based immune evasion pathway is active.
Competitive Advantages
First approach to combine ALDH1A1 inhibitors with cancer immunotherapy.

Request More Info

Licensing Contact: